Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by BearDownAZ


ESPR

Esperion Announces U.S. FDA Acceptance of NDAs

Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for...

May 6, 2019

T.RVX

Updated Van Leeuwenhoeck Report by Marcel Wijma 5/2/2019

Resverlogix - Light at the End of the Tunnel - Targeted 250 MACE Events...

May 2, 2019

T.RVX

RE:The Evolution of Apabetalone, Redux

Re-posting with corrected bad link I found: The understanding of the...

April 26, 2019

T.RVX

The Evolution of Apabetalone, Redux

The understanding of the molecule known as apabetalone (aka RVX-208), as well...

April 26, 2019

T.RVX

Background on Resverlogix, Apabetalone and BETonMACE

This is a copy and paste of what I posted over on Agoracom the other day...

April 23, 2019

T.RVX

RE:RE:Q: Still dosing?

Slide 17 from the Sept 2018 AGM states "Adaptive trial options – stop...

April 18, 2019

T.RVX

RE:Q: Still dosing?

"question tho... are we still dosing? Last visit or treatment visit...

April 18, 2019

T.RVX

RE:RE:RE:RE:RE:RE:RE:Primary and secondary endpoints.....

G1945V, don't ignore the obvious. Last patient study visits and/or phone...

April 18, 2019

T.RVX

RE:RE:RE:RE:RE:Primary and secondary endpoints.....

"With a 90% of MACE already adjudicated I see no reason why they wouldn&...

April 18, 2019

T.RVX

RE:RE:RE:BDZ can you explain this comment?

"Let me ask you what exactly is the “average group value”  for the...

April 13, 2019

T.RVX

RE:BDZ can you explain this comment?

"How is it possible that the “Blinded data” is pointing in the right...

April 13, 2019

V.BTI.H

RE:RE:RE:RE:RE:RE:RE:Big siRNA deal

March 2015 for the news release on this data .......four years ago! It's...

April 9, 2019

V.BTI.H

RE:RE:RE:RE:RE:Big siRNA deal

Correct. We've been waiting for that siRNA article from Bioasis for some...

April 9, 2019

V.BTI.H

Bioasis Corporate Presentation Slide Deck from March 2019

I think this is the first Bioasis slide deck posted to the website...

April 8, 2019

V.BTI.H

RE:RE:RE:Big siRNA deal

It seems that Alnylam is currently relying upon intrathecal injection. ...

April 8, 2019

T.RVX

RE:RE:Patient years

G1945V and Anthonyevans, Resverlogix provided the 8 per 100 patient year...

April 7, 2019

ESPR

ESPR Announces Publication of Bempedoic Acid Study 3 Results

Esperion Announces Publication in The Journal of the American Heart...

April 1, 2019

V.BTI.H

RE:RE:RE:RE:RE:RE:TrainWreck

"And to make deals, we have to show that our technology works in humans,...

March 31, 2019

V.BTI.H

RE:Hey!

Thanks JD. Great to hear from you and great to hear these updates on BiOasis....

March 31, 2019

ESPR

RE:ESPR to present at ACC 2019

Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic...

March 18, 2019